Sponsors (6)
The bill improves and speeds access to non‑opioid chronic pain treatments and reduces out‑of‑pocket costs for Medicare enrollees (especially low‑income beneficiaries), but it raises the risk of higher Part D spending and premiums, potential manufacturer price gaming, and reduced insurer tools to ensure clinically appropriate use.
Medicare beneficiaries with listed chronic pain conditions — including low‑income beneficiaries receiving the Low‑Income Subsidy — will face lower out‑of‑pocket costs for qualifying non‑opioid drugs because Part D deductibles are waived for those drugs and plans must place them on the lowest tier for coinsurance.
Medicare patients with chronic pain can get faster access to non‑opioid treatments and will not be forced to try opioids first because the bill removes opioid‑first requirements and eliminates prior authorization delays for qualifying drugs under Part D and MA‑PD plans.
By lowering financial and administrative barriers to non‑opioid therapies, the policy encourages use of safer alternatives and may reduce opioid exposure, addiction, and overdose among Medicare patients.
Part D spending could rise (and Part D premiums or federal outlays increase) if utilization of more costly qualifying drugs grows — shifting costs onto taxpayers and/or beneficiaries.
Drug manufacturers may raise launch prices up to specialty‑tier thresholds so new products qualify for the benefit, which would sustain or increase high drug prices despite the policy.
Removing certain utilization‑management tools and lowering cost barriers could increase inappropriate or off‑label prescribing and steer patients toward drugs labeled for listed conditions even when clinical benefit over alternatives is unclear.
Based on analysis of 3 sections of legislative text.
For plan years beginning Jan 1, 2026, qualifying non‑opioid chronic pain drugs in Medicare Part D/MA‑PD have no deductible, must be placed on the lowest cost‑sharing tier, and cannot be subject to opioid‑first step therapy or prior authorization.
Official title: Amend title XVIII of the Social Security Act to ensure appropriate access to non-opioid pain management drugs for chronic pain conditions under part D of the Medicare program.
Introduced October 28, 2025 by Steve Daines · Last progress October 28, 2025
Requires Medicare Part D and Medicare Advantage prescription drug plans, beginning January 1, 2026, to treat certain FDA‑labeled non‑opioid drugs for chronic pain as low‑cost drugs: no deductible and placement on the plan’s lowest cost‑sharing tier for calculating maximum coinsurance or other cost‑sharing. Also bans step therapy that forces patients to try an opioid first and prohibits prior authorization for these qualifying non‑opioid chronic pain management drugs. The bill defines qualifying non‑opioid chronic pain management drugs by FDA labeling, therapeutic uniqueness, and a Secretary‑determined wholesale cost cap, and makes conforming changes to low‑income subsidy cost‑sharing rules so the same protections apply to low‑income beneficiaries.